Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

For many years Alzheimer's disease (AD) was associated with the dementia stage of the
disease, the tail end of a pathophysiological process that lasts approximately two decades. …

Alzheimer's disease (AD) has been reconceptualised as a dynamic pathophysiological
process characterized by preclinical, mild cognitive impairment (MCI), and dementia stages. …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s
disease are needed to facilitate the initial screening process of participants in disease-…

Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …

An unresolved question for the understanding of Alzheimer’s disease (AD) pathophysiology
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …

Compelling experimental evidence suggests that microglial activation is involved in the spread
of tau tangles over the neocortex in Alzheimer’s disease (AD). We tested the hypothesis …

… AD patients demonstrated a typical AD CSF biomarkers profile; CSF Aβ42 < 530 ng/L, CSF
p-tau > 60 ng/L, and CSF t-tau > 350 ng/L. The control group consisted of patients with minor …

Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer’s disease (AD), …

Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a …